Education
About Us
Working with TipRanks
Follow Us
Acumen Pharmaceuticals (ABOS)
NASDAQ:ABOS
ABOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $4.28
Previous CloseN/A
Volume101.31K
Average Volume (3M)205.44K
Market Cap
$73.90M
Enterprise Value-$21.36M
Total Cash (Recent Filing)-$6.55M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.40
Next Earnings
May 20, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.70
Shares Outstanding60,079,777
10 Day Avg. Volume211,443
30 Day Avg. Volume205,436
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)14419.15
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.29
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.50
Enterprise Value/Ebitda0.28
Forecast
1Y Price Target
$8.33Price Target Upside577.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe INTERCEPT-AD trial data shows sabirnetug has a remarkable impact on plaque clearance with a differentiated safety profile.
Market PositionSabirnetug is seen as having potential as a best-in-class alternative to existing Alzheimer’s treatments, such as Leqembi and Kisunla.
Safety ProfileThe safety profile of sabirnetug, with no ARIA-E in APOE4 homozygotes, is promising despite the small trial size.
Bears Say
Screening ChallengesThe use of ptau217 screening assays has effectively enrolled and enriched amyloid positive patients for the ALTITUDE-AD, reducing negative screening by nearly 50%.
Trial SizeThe safety profile of sabirnetug is promising despite the small trial size.
---
Ownership Overview
27.76% Insiders
11.06% Mutual Funds
41.87% Other Institutional Investors
13.50% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABOS FAQ
What was Acumen Pharmaceuticals’s price range in the past 12 months?
Acumen Pharmaceuticals lowest stock price was $1.10 and its highest was $4.28 in the past 12 months.
What is Acumen Pharmaceuticals’s market cap?
Acumen Pharmaceuticals’s market cap is $73.90M.
When is Acumen Pharmaceuticals’s upcoming earnings report date?
Acumen Pharmaceuticals’s upcoming earnings report date is May 20, 2025 which is in 52 days.
How were Acumen Pharmaceuticals’s earnings last quarter?
Acumen Pharmaceuticals released its earnings results on Mar 27, 2025. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.514 by -$0.106.
Is Acumen Pharmaceuticals overvalued?
According to Wall Street analysts Acumen Pharmaceuticals’s price is currently Undervalued.
Does Acumen Pharmaceuticals pay dividends?
Acumen Pharmaceuticals does not currently pay dividends.
What is Acumen Pharmaceuticals’s EPS estimate?
Acumen Pharmaceuticals’s EPS estimate is -0.49.
How many shares outstanding does Acumen Pharmaceuticals have?
Acumen Pharmaceuticals has 60,079,777 shares outstanding.
What happened to Acumen Pharmaceuticals’s price movement after its last earnings report?
Acumen Pharmaceuticals reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.514. Following the earnings report the stock price went up 6.034%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals?
Currently, no hedge funds are holding shares in ABOS
---
Acumen Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.33 (577.24% Upside)
$8.33 (577.24% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 100%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 9.2%
Last 30 Days ▼ 9.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.00%
12-Months-Change
Fundamentals
Return on Equity
-45.60%
Trailing 12-Months
Asset Growth
-22.94%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals
Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for the treatment of Alzheimer's disease. With a focus on advancing its proprietary drug candidates, Acumen Pharmaceuticals operates within the biotechnology sector, leveraging innovative research and development to address the unmet medical needs in neurodegenerative diseases.
---
ABOS Company Deck
---
ABOS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and financial stability but also noted substantial operational losses and high instances of mild injection site reactions in a new formulation study.Read More>---
ABOS Stock 12 Month Forecast
Average Price Target
$8.33
▲(577.24% Upside)
Technical Analysis
Best Analysts Covering ABOS
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-45.95%
reiterated a buy rating 2 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -45.95% per trade.
---